BioWorld

Nov. 3, 2006

View Archived Issues

XOMA, Takeda In Antibody Deal With $100M Potential

XOMA Ltd. could receive more than $100 million in a collaboration with Takeda Pharmaceutical Co. Ltd. to discover and develop monoclonal antibody therapeutics. (BioWorld Today) Read More

Exelixis' Stock Falls After XL999 Phase II Suspension

Read More

TopoTarget, LEO Deal Gives CuraGen Payoff For License

Read More

Gamida Cell Earns SPA To Begin Phase III For StemEx

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More